Array Biopharma (ARRY) on watch following positive patent challenge versus Takeda

August 12, 2016 11:01 AM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Array Biopharma (NASDAQ: ARRY) on watch following positive patent challenge versus Takeda.

"The Board has jurisdiction under 35 U.S.C. § 6(c). In this Final Written Decision, issued pursuant to 35 U.S.C. § 318(a) and 37 C.F.R.§ 42.73, we determine that Petitioner has shown by a preponderance of the evidence that claims 1 – 7 and 12
– 16 are unpatentable. Additionally, we deny the Motion to Exclude with respect to Exhibits 1011, 1012, and 1032, and
dismiss the motion with respect to Exhibits 1020 – 1026 and 1033. Also, we deny the Motion to Amend."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

FDA, Trader Talk

Add Your Comment